Overview

Randomised Evaluation of COVID-19 Therapy

Status:
Recruiting
Trial end date:
2031-12-01
Target enrollment:
Participant gender:
Summary
RECOVERY is a randomised trial investigating whether treatment with Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Synthetic neutralizing antibodies (REGN-COV2), Tocilizumab, Aspirin, Baricitinib, Infliximab, Empagliflozin or Anakinra (children only) prevents death in patients with COVID-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Oxford
Collaborators:
Bill and Melinda Gates Foundation
Department for International Development, United Kingdom
Health Data Research UK
Medical Research Council Population Health Research Unit
National Institute for Health Research, United Kingdom
NIHR Clinical Trials Unit Support Funding
NIHR Health Protection Research Unit in Emerging and Zoonotic Infections
UK Research and Innovation
Wellcome
Treatments:
Antibodies
Aspirin
Azithromycin
Colchicine
Dimethyl Fumarate
Empagliflozin
Hydroxychloroquine
Immunoglobulins
Immunoglobulins, Intravenous
Interleukin 1 Receptor Antagonist Protein
Lopinavir
Ritonavir